Ford, H., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F., Wadsley, J., . . . Dunn, J. A. (2014). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): An open-label, phase 3 randomised controlled trial. Elsevier.
Chicago Style (17th ed.) CitationFord, Hugo, et al. Docetaxel Versus Active Symptom Control for Refractory Oesophagogastric Adenocarcinoma (COUGAR-02): An Open-label, Phase 3 Randomised Controlled Trial. Elsevier, 2014.
MLA (9th ed.) CitationFord, Hugo, et al. Docetaxel Versus Active Symptom Control for Refractory Oesophagogastric Adenocarcinoma (COUGAR-02): An Open-label, Phase 3 Randomised Controlled Trial. Elsevier, 2014.
Warning: These citations may not always be 100% accurate.